Home › Funds › Elmind Capital, LP › CLDX
Elmind Capital, LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Elmind Capital, LP reported holding 990,000 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q2 2026 13F filing — a position valued at US$36.8M, representing 9.25% of its reported portfolio and ranking #3 among its reported holdings. Elmind Capital, LP has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's CLDX position evolved
Elmind Capital, LP first disclosed a stake in CLDX in Q4 2025 at 865,000 shares (US$23.5M). The position peaked in Q2 2026 at 990,000 shares, worth US$36.8M. Across 3 filings, Elmind Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 990,000 shares valued at US$36.8M — an increase of 125,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 865.00K | $23.49M | New |
| Q1 2026 | 865.00K | $27.44M | Hold |
| Q2 2026 | 990.00K | $36.84M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 43 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.32M sh · $198.07M · Q2 2026
- Deep Track Capital, LP 2.94M sh · $109.37M · Q2 2026
- Logos Global Management LP 2.10M sh · $78.14M · Q2 2026
- Eversept Partners, LP 1.79M sh · $66.45M · Q2 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- Affinity Asset Advisors, LLC 700.00K sh · $26.05M · Q2 2026
- Rock Springs Capital Management LP 699.15K sh · $26.02M · Q2 2026
- ADAR1 Capital Management, LLC 619.54K sh · $23.05M · Q2 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held CLDX?
Elmind Capital, LP has disclosed CLDX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in CLDX?
As of Q2 2026, Elmind Capital, LP holds 990.00K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $36.84M, representing 9.25% of its reported portfolio and ranking #3.
Has Elmind Capital, LP been buying or selling CLDX?
In the latest 13F filing (Q2 2026), Elmind Capital, LP increased its position in CLDX. The position peaked in Q2 2026 at 990.00K shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.